Cardiac and cerebral manifestations of the antiphospholipid syndrome

Hamostaseologie

Volumn 21, Issue 2, 2001, Pages 60-65

  Jung, F ^a   Scharrer, I ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Antiphospholipid syndrome; Cerebral manifestations; Coronary artery disease; Myocardial infarction; Valvular disease

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BRAIN INFARCTION; CLINICAL ARTICLE; CORONARY ARTERY THROMBOSIS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENDOCARDITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; MALE; REVIEW; VALVULAR HEART DISEASE;

EID: 0034929879     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619505     Document Type: Review

References (70)

1. Criteria for the diagnosis of lupus anticoagulants: An update
2. Antiphospholipid antibody syndrome
3. The "primary"; antiphospholipid syndrome: Major clinical and serological features
4. Clinical consequences of antiphospholipid antibodies: An historic cohort study
5. Immunology and clinical importance of antiphospholipid antibodies
6. The heart and antiphospholipid antibodies. Personal experience and review of the literature
7. Vascular disease in the antiphospholipid syndrome: A comparison with the patient population with atherosclerosis
8. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance
9. Pulmonary hypertension in systemic lupus erythematosus: A report of three cases
10. Pulmonary hypertension and systemic lupus erythematosus
11. The family history of patients with primary or secondary antiphospholipid syndrome (APS)
12. HLA-DR antigens and anticardiolipin antibodies
13. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - A crucial role for acquired free protein S deficiency
14. Antibody-mediated disruption of the annexin-V antithrombotic shield: A new mechanism for thrombosis in the antiphospholipid syndrome
15. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: Lack of correlation with antiphospholipid antibodies
16. Cardiac involvement in connective tissue diseases and primary antiphospholipid syndrome: Echocardiographic assessment and correlation with antiphospholipid antibodies
17. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus
18. Primary antiphospholipid syndrome and cardiovascular disease
19. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA
20. Recurrent acute coronary events in a patient with primary antiphospholipid syndrome: Successful management with intracoronary stenting
21. Right ventricular thrombus after pacemaker implantation in a patient with secondary antiphospholipid syndrome
22. High prevalence of significant heart valve lesions in patients with the 〉primary〈 antiphospholipid syndrome
23. Cardiac involvement in patients with primary antiphospholipid syndrome
24. Valvular heart disease in the primary antiphospholipid syndrome
25. Valvular heart disease in primary antiphospholipid syndrome (PAPS): Clinical and morphological findings
26. Neurological aspects of antiphospholipid antibody syndrome
27. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children
28. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome
29. Hughes syndrome: Antiphospholipid syndrome
30. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood
31. Fatal cerebral venous thrombosis as the initial manifestation of the antiphospholipid syndrome
32. Anticardiolipin antibodies: A study in cerebral venous thrombosis
33. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: Association with antiphospholipid antibodies
34. Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome
35. The catastrophic antiphospholipid syndrome 1996: Acute multi-organ failure associated with antiphospholipid antibodies: A review of 31 patients
36. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events
37. Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome
38. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men
39. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome
40. High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease
41. Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome
42. Atherosclerosis in SLE and Hughes syndrome
43. Antiphospholipid antibodies and atherosclerosis
44. Antibodies to oxidised LDL
45. Clinical significance of anti-beta 2-glycoprotein I antibodies
46. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome
47. IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: Comment on the article by Sammaritano et al.
48. Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus
49. Findings at necropsy in the heart of a patient with anticardiolipin syndrome
50. Cardiac manifestations of the antiphospholipid syndrome
51. Post-partum dilated cardiomyopathy in antiphospholipid positive woman
52. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome
53. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus
54. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies
55. Valvular heart disease in systemic lupus erythematosus
56. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus
57. Valvular dysfunction in antiphospholipid syndrome: Prevalence, clinical features, and treatment
58. Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic 〉rheumatic type〈 valvular heart disease
59. Prevalence and description of cardiac involvements in primary antiphospholipid syndrome
60. Cerebral infarction in systemic lupus: Association with anticardiolipin antibodies
61. Primary antiphospholipid syndrome: Features of patients with raised anticardiolipin antibodies and no other disorder
62. Antiphospholipid antibodies and chorea
63. Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis
64. The antiphospholipid syndrome
65. Antiphospholipid antibodies in cerebral ischemia
66. Cerebrovascular ischemic events with high positive anticardiolipin antibodies
67. Anticardiolipin antibody and stroke: Possible relation of valvular heart disease and embolic events
68. Anticardiolipin antibody aggravates cerebral vasospasm after subarachnoid hemorrhage in rabbits
69. Platelet-activating factor and antiphospholipid antibodies in subarachnoid haemorrhage
70. Echocardiographic evaluation of patients with primary antiphospholipid syndrome